Croda introduces Zenakine at global cosmetics event

Published 08/04/2025, 11:02
Croda introduces Zenakine at global cosmetics event

AMSTERDAM - SkinBioTherapeutics plc (AIM: SBTX) has announced that its partner Croda (LON:CRDA) plc unveiled a new neuroactive skincare ingredient, Zenakine™, at in-cosmetics Global, the premier event for the cosmetic ingredients industry. The ingredient, formerly known as SkinBiotix™, is touted to mitigate stress effects on the skin and enhance overall well-being.

Zenakine™ is formulated to work in harmony with the skin's natural biological rhythms, promoting melatonin production to aid sleep quality, boost positive emotions, and stimulate skin regeneration. Clinical studies have shown that users experience a 13.5% increase in happiness, an 11.3% improvement in sleep quality, and a 13.3% lifting effect on skin fatigue signs, all compared to a placebo after one month of use.

The product's benefits extend to consumer well-being, offering improved skin resilience against stress, smoother skin, and better emotional balance. Zenakine™ is produced through biotechnology, ensuring 100% natural-origin content and adherence to RSPO and COSMOS standards, reflecting a commitment to sustainability.

For formulators, Zenakine™ represents a significant innovation, combining scientific efficacy with emotional wellness benefits. It's designed to be a multifunctional solution that supports skin health while fostering well-being, providing a sustainable option for clean cosmetic formulations.

Applications for Zenakine™ include eye contour, face and neck skincare, and scalp treatments. Croda has launched the ingredient in various formulations, such as serums, beauty mists, masks, and creams.

The commercial terms between SkinBioTherapeutics and Croda, which involve tiered royalties based on global sales, remain confidential due to market competitiveness. The company will report any future royalty revenues at the appropriate time.

Stuart Ashman, CEO of SkinBioTherapeutics, expressed excitement about the launch, noting the anticipation from the team and investors. He highlighted Croda's claim that Zenakine™ is the first scientifically proven anti-aging active ingredient, which is expected to generate significant interest in the cosmetics industry.

Based on a press release statement, the information on Zenakine™'s launch and its potential impact on the cosmetics market is now public. Further updates, including half-year results and details on the launch, will be presented by the SkinBioTherapeutics management team in an upcoming webinar scheduled for April 16, 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.